In the latest milestone push, HEARTio has built a path toward FDA clearance after securing a Breakthrough Device designation in 2020, two pivotal clinical studies with large patient cohorts demonstrating strong sensitivity and specificity (2021 study with 1,659 patients at 93% sensitivity and 87% specificity; 2026 study with 16,476 patients at 91% sensitivity and 89% specificity), three issued patents, and a letter of intent with Cardiology Consultants of Philadelphia, alongside a Series A commitment from Shepherd Ventures III.

The core product ECGio analyzes a standard 12-lead ECG to estimate plaque burden across the major coronary arteries, stratify risk, and integrate results into existing EHR workflows, turning an inexpensive ECG into a comprehensive diagnostic tool.

CEO and co-founder Utkars Jain brings a multidisciplinary background in applied math, neuroscience, bioengineering, and an MBA from Wharton, driven by personal tragedy from a grandfather’s misdiagnosis.

The total addressable market for applicable ECGs tops $23 billion globally, with a US serviceable market around $3 billion and near-term obtainable market near $300 million, and a long-term plan to expand through new indications, wearables, and OEM integrations with major ECG hardware providers to accelerate adoption.

MedTech challenges include coordinating FDA clearance, overcoming clinician skepticism toward AI (which is easing with generative AI), and implementing ongoing risk management strategies to de-risk the path to approval and commercialization.

The company’s technology has evolved rapidly, expanding from datasets to over 14 million ECGs, enabling broader outputs and new clinical questions, with a roadmap targeting multiple cardiac indications and a goal to replace costly tests with a quick 10-second ECG.

A highlighted milestone is securing initial funding to commit full-time to HEARTio, with the company having raised more than $6.5 million and winning over $140,000 in pitch competitions.

Jain’s daily routine blends AI model development with business development, including investor meetings and hospital partnerships, while finalizing a pivotal FDA study and building a commercial pipeline.

HEARTio’s flagship AI-powered cardiac diagnostic suite analyzes standard ECGs to detect coronary artery disease in under a minute without specialized hardware, radiation, dyes, or invasive procedures, positioning ECGio at the forefront of its strategy.

The idea originated at the University of Pittsburgh, with early collaboration among co-founders Michael Leasure and Adam Butchy and initial clinical support from Cardiology Consultants of Philadelphia and the Cardiovascular Research Foundation; the company was incorporated in 2018.

Funding and revenue trajectory shows $1.8 million in pre-seed and $4.25 million raised in seed toward a $7 million target, with pre-commercial status pending FDA clearance and projected revenue growth from about $5 million in 2027 to $170 million by 2031; Series A commitment is in place.

Competitive edge centers on point-of-care use with standard ECGs, avoiding CT or costly hardware, delivering roughly 90% accuracy in under a minute with zero radiation and minimal workflow disruption, backed by 14 million proprietary ECGs and a decade of outcome data, plus FDA Breakthrough Device Designation and three patents as it claims to uniquely infer anatomic coronary disease from any ECG.